ACTG 368--INDINAVIR SULFATE, DMP266, & 1592U89 IN HIV INFECTED SUBJECTS

ACTG 368--硫酸茚地那韦，DMP266，

• 批准号: 6274553
• 负责人: ROB R MCGREGOR
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-15 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274553
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clinical research; clinical trials; drug screening /evaluation; human subject; human therapy evaluation; nucleoside analog; protease inhibitor; reverse transcriptase inhibitors; virus load

The purpose of this study is to compare the virologic response across the study arms with respect to: * The proportion of study subjects with plasma HIV RNA levels below the limit of detection (<200 copies/ml) at week 16. * Time to detectable viremia (2 consecutive plasma HIV RNA levels >= 200 copies/ml). And to also evaluate the safety and tolerance of the study arms.

这项研究的目的是比较跨越病毒学反应 研究有关： *血浆HIV RNA水平的研究受试者的比例低于 第16周的检测限（<200份/ml）。 *时间可检测的病毒血症（连续2个血浆HIV RNA水平> = 200份/毫升）。 并评估研究臂的安全性和耐受性。